Why did AbbVie terminate the Bridge Credit Agreement?

AbbVie terminated the Bridge Credit Agreement because it has sufficient cash on hand to fund the acquisition of Allergan plc and related expenses, making the credit facility unnecessary. This demonstrates strong liquidity and financial planning.

What was the purpose of the Bridge Credit Agreement?

The Bridge Credit Agreement, with a potential of up to $38.0 billion, was established to provide financing for the cash consideration of AbbVie's acquisition of Allergan plc, associated fees and expenses, and to repay certain existing indebtedness of Allergan.

Does this termination mean the Allergan acquisition is canceled?

No, the termination of the financing agreement does not indicate a cancellation of the Allergan acquisition. Instead, it signifies that AbbVie has secured the necessary funds through its existing cash reserves.

What are the financial implications of this termination for AbbVie?

The termination eliminates the potential need for AbbVie to incur $38.0 billion in debt for the acquisition, which is a positive development for its balance sheet and reduces future interest expenses. It also signals a stronger financial position for executing the acquisition.

ABBV 8-K: Material Agreements

Summary

AbbVie Inc. (ABBV) filed an 8-K on February 14, 2020, to announce the termination of its 364-Day Bridge Credit Agreement. This agreement, initially established on June 25, 2019, with a borrowing capacity of up to $38.0 billion, was intended to finance AbbVie's acquisition of Allergan plc, associated fees, and Allergan's existing debt. The termination signifies a positive development as it indicates AbbVie has sufficient cash on hand to fund the Allergan acquisition without needing to draw upon this significant credit facility. This reduces the company's potential debt obligations related to the acquisition financing.

Key Highlights

1Termination of the $38.0 billion 364-Day Bridge Credit Agreement.
2The agreement was originally intended to finance the acquisition of Allergan plc.
3The termination is effective as of February 11, 2020.
4The reduction of commitments to $0 is due to AbbVie having sufficient cash on hand.
5All accrued and unpaid fees under the terminated agreement have been paid.
6This action signals a deleveraging or reduced reliance on external financing for the Allergan deal.
7The filing was signed by Robert A. Michael, Executive Vice President and Chief Financial Officer.

AbbVie Inc. 8-K Report, Agreement Terminated (Feb 14, 2020)

Summary

Key Highlights

Frequently Asked Questions